Tehran Holds the Line on Cannabis as Opium Remains the Dominant Drug of Use

On 22 June 2026, the secretary general of Iran's Anti-Narcotics Headquarters, Zulfiqari, told state-aligned outlet Tasnim that marijuana legalisation is "not on the agenda" and that cannabis is not part of the country's formal treatment protocols. In a separate exchange the same morning, Zulfiqari acknowledged that opium remains the principal drug used in the country, even as official statistics show a meaningful shift away from it. The two remarks, delivered within minutes of each other, summarise a drug policy that is still framed in the language of interdiction and public order rather than harm reduction.

The decision to keep cannabis criminalised is consistent with Iran's long-standing posture. The Islamic Republic sits along the main Balkan and southern trafficking routes for Afghan opiates and has invested heavily in supply-side enforcement. The cost — measured in seizures, in security-force casualties, and in the world's highest per-capita rate of drug-related incarceration — has been central to how Tehran justifies its drug laws at international forums. The legalisation question, by contrast, has been treated as a Western policy export that the Iranian state has no interest in importing.

What was actually said

Tasnim's reporting on 22 June 2026 carries Zulfiqari's two statements in plain terms. On cannabis, the position is that legalisation is not under consideration. The outlet frames the question as one raised by some treatment programs abroad; Zulfiqari's answer draws a line: what is followed elsewhere in substitution or harm-reduction protocols is not on the table in Iran. On opium, the same official confirmed that it is still considered the main drug used in the country, while adding that statistics show a significant change in the consumption pattern. The hedging — "still," "significant change," "considered" — is itself a signal: the official epidemiological picture is moving, but the policy frame has not.

For a reader unfamiliar with Iran's drug market, the most important context is the asymmetry. Cannabis is a secondary substance in the official consumption profile, used in ways that are culturally familiar but politically loaded. Opium and its derivatives — and the methamphetamines and synthetic opioids that have entered the market over the last decade — are the substances driving the country's treatment, interdiction, and incarceration numbers. The legalisation debate, where it exists at all inside Iran, is a debate about a substance that is not the principal driver of harm.

The security frame, intact

Iran's drug policy has historically been narrated through the lens of national security: porous eastern borders, transit geography, and the cost borne by Iranian security forces. The position of the Anti-Narcotics Headquarters, an inter-ministerial body under the interior ministry, reflects that frame. The 2026 statement reproduces it. There is no public acknowledgement in the Tasnim exchanges that harm-reduction approaches — opioid substitution therapy, needle exchange, supervised consumption — have evidence bases of their own. The argument inside the Iranian policy system is that the country's exposure is structural, not behavioural, and that the appropriate response is interdiction backed by the death penalty for certain trafficking offences.

This is also where the international comparison is most uncomfortable. Iran executes more people for drug offences than any other country, according to longstanding reporting from human-rights monitors and Western wires, and the trend has been repeatedly raised by UN human rights bodies. The Iranian state's response, when the question is raised, is to point at the volume of seizures — multi-tonne opium and methamphetamine hauls that, taken together, would constitute a substantial share of the global supply if the figures are taken at face value — and to argue that the severity of penalties is a function of geography and exposure. Zulfiqari's 22 June remarks are in line with that posture: a refusal to consider regulatory reform is treated as a reasonable response to a security problem, not a public-health one.

What the data suggests, and what it does not

Tasnim's report flags a "significant change" in consumption patterns, but the underlying figures are not in the wire and the secretary general did not cite them. Two things can be said safely. First, opium is still the main drug used in the country, by the official's own account — which means the demand-side profile is dominated by a substance for which a regulated, pharmaceutical-substitution approach has decades of evidence in other jurisdictions. Second, the legalisation debate being dismissed is about cannabis, a substance that is not the principal driver of treatment demand. The two facts are not in tension, but they do mean the policy position is being framed as a defence against the larger drug problem while the reform proposal on the table is about a smaller one.

There is a counter-narrative worth naming. Some Iranian public-health researchers and reform-aligned voices have argued, in papers and in interviews with Persian-language outlets outside state control, that the security-first frame has been allowed to crowd out pragmatic harm-reduction measures that could reduce transmission of HIV and hepatitis C among the injecting population. The Tasnim wire does not engage with that line; the headquarters' public position does not engage with it either. The framing the public hears is that legalisation is a Western distraction and that the country's drug problem is best handled through enforcement. Whether that framing is accurate, partial, or outdated is not a question this wire can answer; the materials provided do not contain the data needed to settle it.

Stakes and what to watch next

The decision has practical consequences. Iran sits on one of the world's most consequential drug transit corridors and absorbs an outsized share of the regional interdiction burden. If the consumption profile is in fact shifting — toward synthetic stimulants, as reporting over the last several years has suggested — the policy frame that treats opium as the principal enemy is, in operational terms, a frame looking at the wrong chart. The headquarters' continued public commitment to the opium-era frame is therefore a leading indicator of whether Iran's drug policy will adapt to its own epidemiological data or will continue to subordinate public health to the security argument.

The international dimension is also worth flagging. The opium supply Iran has historically interdicted has been overwhelmingly Afghan. With Afghan production and trafficking patterns in flux since 2021, the supply picture has changed in ways the public statements do not yet engage with. A policy apparatus built for the opium era of the 2000s is being asked to police a more complex market, and the 22 June remarks do not signal that the apparatus is recalibrating. For now, the official line is firm: no legalisation, no harm-reduction framing, and opium, however displaced, is still the principal problem.

This article draws on two wire items from Tasnim, dated 22 June 2026. Monexus has reproduced the secretary general's reported positions without embellishment; the consumption-data gap is noted above as a limitation of the source set.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://t.me/s/tasnimnews_en
• https://t.me/s/tasnimnews_en
• https://en.wikipedia.org/wiki/Drug_policy_of_Iran
• https://en.wikipedia.org/wiki/Anti-Narcotics_Headquarters_(Iran)
• https://en.wikipedia.org/wiki/Opium_production_in_Afghanistan